Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer

Journal of Infection and Chemotherapy

Volumn 18, Issue 6, 2012, Pages 807-815

  Sasagawa, Toshiyuki ^a   Takagi, Hiroaki ^a   Makinoda, Satoru ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adaptive immunity; Cervical cancer; Human papillomavirus; Immune evasion; Immune tolerance; Innate immunity

Indexed keywords

HLA ANTIGEN CLASS 1; INTERFERON; PROTEIN E2; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; CANCER PREVENTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HOST RESISTANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS REPLICATION; WART VIRUS; ANIMAL; BIOLOGICAL MODEL; FEMALE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PAPILLOMA VIRUS; UTERINE CERVIX TUMOR; VIROLOGY;

ANIMALS; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, IMMUNOLOGICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84880418304     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0485-5     Document Type: Review

References (42)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50. (Pubitemid 37328947)
2. Shigehara K, Sasagawa T, Kawaguchi S, Nakashima T, Shimamura M, Maeda Y, et al. Etiologic role of human papillomavirus infection in bladder carcinoma. Cancer. 2011;117:2067-76.
3. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70-9.
4. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27. (Pubitemid 36159887)
5. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-56.
6. Matsukura T, Sugase M. Human papillomavirus genomes in squamous cell carcinomas of the uterine cervix. Virology. 2004;324:439-49. (Pubitemid 38797860)
7. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev. 2001;10:45-52. (Pubitemid 32106043)
8. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525-41. (Pubitemid 43736116)
9. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health. 2005;37:S3-9 (review).
10. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol. 2011;27:597-604.
11. Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res. 2009;130:266-76.
12. Palefsky J. Human papillomavirus-associated malignancies in HIV-positive men and women. Curr Opin Oncol. 1995;7:437-41.
13. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 2002;62:472-509.
14. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 2003;63:636-41. (Pubitemid 36158141)
15. Welters MJP, van der Logt P, van den Eeden SJF, Kwapenberg KMC, Drijfhout JW, Fleuren GJ, et al. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer. 2006;118:950-6. (Pubitemid 43157670)
16. Yamada R, Sasagawa T, Kirumbi LW, Kingoro A, Karanja DK, Kiptoo M, Nakitare GW, Ichimura H, Inoue M. Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. J Med Virol. 2008;80:847-55. (Pubitemid 351500033)
17. Rahman M, Sasagawa T, Yamada R, Kingoro A, Ichimura H, Makinoda S. High prevalence of intermediate-risk human papillomavirus infection in uterine cervices of Kenyan women infected with human immunodeficiency virus. J Med Virol. 2011;83:1988-96.
18. Grandvaux N, tenOever BR, Servant MJ, Hiscott J. The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis. 2002;15:259-67. (Pubitemid 34548188)
19. Koromilas AE, Li S, Matlashewski G. Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev. 2001;12:157-70. (Pubitemid 32588142)
20. Rincon-Orozco B, Halec G, Rosenberger S, Muschik D, Nindl I, Bachmann A, Ritter TM, Dondog B, Ly R, Bosch FX, Zawatzky R, Rösl F. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res. 2009;69:8718-25.
21. Routes JM, Morris K, Ellison MC, Ryan S. Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms. J Virol. 2005;79:116-23. (Pubitemid 39648369)
22. Hacke K, Rincon-Orozco B, Buchwalter G, Siehler SY, Wasylyk B, Wiesmüller L, Rösl F. Regulation of MCP-1 chemokine transcription by p53. Mol Cancer. 2010;9:82-94.
23. Guess JC, McCance DJ. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol. 2005;79:14852-62. (Pubitemid 41636283)
24. Laffort C, Le Deist F, Favre M, Caillat-Zucman S, Radford-Weiss J, Debre M, et al. Severe cutaneous papillomavirus disease after haematopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet. 2004;363:2051-4. (Pubitemid 38781108)
25. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Dueñas MG, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer. 2009;9:186-94.
26. Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K, Kojima S, Yasugi T, Kozuma S, Taketani Y. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol. 2010;84(22):11614-23.
27. Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005;174:7172-8. (Pubitemid 40705684)
28. Leong CM, Doorbar J, Nindl I, Yoon HS, Hibma MH. Deregulation of E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types. Br J Dermatol. 2010;163:1253-63.
29. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis. 1997;175:927-31. (Pubitemid 27142969)
30. Dillon S, Sasagawa T, Crawford A, Prestidge J, Inder MK, Jerram J, et al. Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2. J Gen Virol. 2007;88:803-13. (Pubitemid 46359549)
31. Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis. 2010;14:124-9.
32. Campo MS, Graham SV, Cortese MS, Ashrafi GH, Araibi EH, Dornan ES, Miners K, Nunes C, Man S. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology. 2010;407(1):137-42.
33. Tindle RW. Immune evasion in human papillomavirus associated cancer. Nat Rev Cancer. 2002;2:59-65. (Pubitemid 37328808)
34. Azar KK, Yasuda H, Tani M, Basha W, Sakai A, Inoue M, Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol. 2004;35:1376-84. (Pubitemid 39601578)
35. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007;98:874-81. (Pubitemid 46691826)
36. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010;102:1129-36.
37. Sasagawa T, Inoue M, Yutsudo M, Tanizawa O, Hakura A. Identification of antibodies against HPV 16 E6 and E7 proteins in the sera of patient with cervical neoplasia. Jpn J Cancer Res. 1992;83:705-13.
38. Sasagawa T, Yamazaki H, Dong YZ, Satake S, Tateno M, Inoue M. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intraepithelial lesions. Int J Cancer. 1998;75:529-35. (Pubitemid 28094097)
39. Sasagawa T, Rose RC, Azar KK, Sakai A, Inoue M. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids. Int J Cancer. 2003;104:328-35. (Pubitemid 36249815)
40. Tiggelaar SM, Lin MJ, Viscidi RP, Ji J, Smith JS. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health. 2012;50:110-31.
41. Kim S, Arduino JM, Roberts CC, Marsico M, Liaw KL, Skjeldestad FE. Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young Norwegian women. Sex Transm Dis. 2011;38:587-97.
42. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377:2085-92.